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Genetic disease therapyHumans have two nearly identical copies of survival motor neuron gene: SMN1 and SMN2. Deletion or mutation
of SMN1 combined with the inability of SMN2 to compensate for the loss of SMN1 results in spinal muscular at-
rophy (SMA), a leading genetic cause of infant mortality. SMA affects 1 in ~6000 live births, a frequency much
higher than in several genetic diseases. The major known defect of SMN2 is the predominant exon 7 skipping
that leads to production of a truncated protein (SMNΔ7), which is unstable. Therefore, SMA has emerged as a
model genetic disorder in which almost the entire disease population could be linked to the aberrant splicing
of a single exon (i.e. SMN2 exon 7). Diverse treatment strategies aimed at improving the function of SMN2
have been envisioned. These strategies include, but are not limited to, manipulation of transcription, correction
of aberrant splicing and stabilization of mRNA, SMN and SMNΔ7. This review summarizes up to date progress
and promise of various in vivo studies reported for the treatment of SMA.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Spinalmuscular atrophy (SMA) is a genetic disease caused by homo-
zygous deletion, truncation, mutation or gene conversion of survival
motor neuron 1 (SMN1) [1–4]. SMN2, a nearly identical copy of SMN1,
fails to compensate for the loss of SMN1 owing to a cytosine to thymi-
dine mutation at the 6th position (C6U in the transcript) of exon 7.
C6U triggers predominant skipping of SMN2 exon 7 due to disruption
of an exonic splicing enhancer and/or creation of an exonic splicing
silencer [5–7]. The resultant decrease in full-length transcript reduces
functional SMN, since the translated product (SMNΔ7) of the truncated
transcript is unstable and rapidly degraded [8–10]. The copy number of
SMN2 modulates the severity of SMA: the more SMN2 copies the less
severe the disease due to higher levels of the full-length transcript and, antisense oligonucleotide; BBB,
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ights reserved.functional SMN [11–13]. Thus, treatment strategies to halt the disease
progression and ameliorate the symptoms have primarily focused on
means to increase full-length SMN2 transcript and functional SMN.
The multifunctional SMN has been implicated in snRNP biogenesis
[14–17], transcription [18,19], splicing [20], translation [21], signal
transduction [22], stress granule formation [23] and intra-cellular traf-
ﬁcking [24].With respect to neuron-speciﬁc functions, SMN facilitates in-
teraction of mRNA binding proteins and participates in mRNA transport
across the axonal processes of motor neurons [25–27]. SMN modulates
axon outgrowth and cytoskeletal dynamics through β actin localization
[28–30]. Preventing SMN transport across axons causes growth cone
collapse [31]. SMN also plays an important role in postnatal muscle
nerve terminal maturation and reduction in SMN levels is predicted to
negatively affect neurotransmission [32]. Defects in snRNP biogenesis
correlate with the severity of SMA, although only a subset of snRNPs
is preferentially affected [33]. Supporting these arguments, motor neu-
rons of Smn deﬁcient Drosophila show decreased expression of a subset
of certain genes containing the U12 type introns [34].
Mice, unlike humans, possess only one Smn gene, and homozygous
deletion of Smn is embryonically lethal [35]. Several transgenic mouse
models thatmimic the SMApathology have been developed by introduc-
ing human SMN2 into themouse genome in the context of Smn knockout.
Two recent excellent reviews describe these models in much detail
[36,37]. Preclinical research to identify promising treatments for SMA
has relied heavily upon these murine models [22,38–48]. Table 1
lists a few major mouse models utilized in preclinical trials as well
as a few other models that may be exploited for these pursuits. Two
severe mouse models account for the majority of preclinical studies:
the Taiwanese model [38,48] and the Δ7 SMA model [40]. Generally,
therapeutic strategies in SMA mice focused on increasing the amount
Table 1
Mouse models useful for testing drug efﬁcacy for potential SMA therapy.
Model Genotype Survival (days) Outcome measures References
Taiwanese Smn−/−; SMN2(2Hung)+/± [mice carry 1 or 2
copies of transgene]
Type I: ~10
Type II: ~14
Type III: Normal
Survival; motor function; tail and limb necrosis;
motor neuron, NMJa, muscle and heart morphology
and/or function
[38,48]
Line89 Smn−/−; SMN2(89Ahmb)+/+ 5 Survival; motor function; motor neuron, NMJ and
muscle morphology and/or function
[39]
Δ7 SMA Smn−/−; SMN2(89Ahmb)+/+; SMNΔ7+/+ ~14 Survival; motor function;motor neuron, NMJ, muscle
and cardiac morphology and/or function
[40]
3 copy SMN2 Smn−/−; SMN2(N11); SMN2(N46) 14–16 Survival; motor function; motor neuron, NMJ and
muscle morphology and/or function
[41]
F7 or exon 7 ﬂoxed SmnF7/Δ7; NSE-Cre [exon 7 loss in neurons] 25 Survival; motor function; motor neuron, NMJ and
muscle morphology and/or function
[43]
F7 or exon 7 ﬂoxed SmnF7/Δ7; HSA-Cre [exon 7 loss in skeletal muscle] 33 Survival; motor function; motor neuron, NMJ and
muscle morphology and/or function
[42]
2B Smn2B/− [2B is deﬁned by mutation in exon 7
splicing enhancer]
~30 Survival; motor function; neuromuscular junction
and muscle morphology and/or function
[22]
SMNRT Smn−/−; SMN2(89Ahmb)+/+; SMNΔ7RT +/+ 34 Survival; motor function; motor neuron, NMJ and
muscle morphology and/or function
[44]
Olig2-Cre SmnF7/−; SMN2(89Ahmb)+/+; Olig2-Cre [exon 7
loss in motor neuron progenitor cells]
365b Motor function; motor neuron, NMJ and muscle
morphology and/or function
[45]
Smn C N T SmnC N T [SMN2mutation inserted in mouse Smn] Normal Motor function; motor neuron, NMJ and muscle
morphology and/or function
[46]
Allele C SmnC/C [C is deﬁned by a chimeric gene plus SMN2] Normal Ear, tail and limb necrosis; cardiac morphology and
function
[47]
a NMJ, neuromuscular junction.
b 70% of these mice survived to 365 days.
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and correct tissue and motor function abnormalities. We summarize
the major avenues of therapeutic interventions explored for SMA with
particular emphasis on small molecules and antisense oligonucleotides
(ASOs). This review complements a recent report that describes in
detail the progress in the ﬁeld of ASO-mediated therapy of SMA [49].
Due to lack of space and the staggering number of compounds tested
for SMA therapy, we are unable to provide details on dose, duration
and frequency of delivery for most of the compounds. For the purposes
of comparison, we have put major emphasis on the life expectancy as
the primary measure of the therapeutic efﬁcacy in severe SMA mice.
Until two years ago there was no report of a therapeutic compound
that could extend the lifespan of a severe SMA mouse beyond
30 days. Recently, independent studies have shown an impressive
increase in the life expectancy of severe SMA mice treated with ASOs
that speciﬁcally target an intronic sequence within SMN2 [refs. in 49].
The noticeable aspect of these studies is the cross validation of ASO ef-
ﬁcacy among various mouse models and oligonucleotide chemistries
against the same intronic target (described later). However, due to
timing of blood brain barrier (BBB) formation and several other features
distinct from humans, results in mouse models of SMA should be
interpreted with caution. An overwhelming majority of small com-
pounds confer a modest (b1.5-fold) increase in the life expectancy of
severe SMA mice (Fig. 1). Consistently, these compounds display poor
efﬁcacy in clinical trials. However, possibilities remain that some of
these compounds could be further improved to achieve a better thera-
peutic efﬁcacy.
2. Treatment with small compounds
Small compounds offer several advantages, including an easy trans-
port across biological barriers. Considering SMA is a neurodegenerative
disease, compounds that are transported across BBBwould be best suit-
ed for an effective therapy. A summary of the relative efﬁcacy of small
compounds and other treatments is given in Fig. 1 [based on refs.
50–82]. Available reports underscore the diversity of processes that
may impact SMN2 transcription, SMN2 exon 7 splicing and/or SMNlevels within a cell. Given below are the major classes of compounds
that have been tested for their efﬁcacy for SMA therapy (Table 2).
2.1. Histone deacetylase (HDAC) inhibitors
HDAC inhibitors prevent deacetylation of histones and increase
gene expression through chromatin remodeling [83,84]. Various
chemical classes of HDAC inhibitors have been shown to enhance
the expression of SMN2 in SMA patient cells and in mouse models
of SMA (Fig. 1) [68,69,80,81,85–88]. Sodium butyrate modestly in-
creased survival in Taiwanese type II mice and reduced tail necrosis
[81]. Valproic acid (VPA), a FDA-approved compound with multiple
functions including HDAC inhibition, increased motor neuron density
in the lumbar spinal cord and ameliorated necrosis of the tail and ears
of Taiwanese type III mice [89]. In a follow-up study, type III SMA
mice treated with VPA exhibited decreased spinal cord motor neuron
degeneration, decreased muscle atrophy and improved neuromuscular
junction innervation [90]. However, the effects of VPA in severe SMA
micewere less pronounced. Nevertheless, VPA has been extensively ex-
amined as a treatment for types I, II and III SMA patients in several clin-
ical trials (Clinicaltrials.gov ID numbers NCT00661453, NCT00227266,
NCT00374075, NCT00481013, and NCT01671384). The beneﬁcial ef-
fects of VPA in SMA patients, however, have been nominal [91–95]. An-
other HDAC inhibitor, phenylbutyrate, has been trialed in SMA patients
with modest results [96], although more extensive clinical trials have
been terminated due to poor treatment compliance or slow enrollment
(Clinicaltrials.gov ID numbers NCT00439569 and NCT00439218).
Trichostatin A (TSA), a second-generation HDAC inhibitor, improved
motor function and modestly increased the survival of Δ7 SMA mice
(Fig. 1) [69]. Addition of a nutritional supplement with TSA treatment
augmented the beneﬁcial effects, including a ~2.5-fold increase in
lifespan of Δ7 SMA mice (Fig. 1) [68]. Suberoylanilide hydroxamic acid
(SAHA), another second-generation HDAC inhibitor, rescued the em-
bryonic lethality and modestly increased survival of Taiwanese type I
SMA mice (Fig. 1) [80]. However, higher doses of SAHA resulted in tox-
icity even in heterozygousmice [80]. A recent study with SAHA showed
weight gain and improved motor function in Taiwanese type I SMA
Fig. 1. Survival bar charts of treatments in Δ7 SMA mice and Taiwanese SMA mice. (A) Survival bar charts comparing control and treatment in Δ7 SMA mice. *, still alive at N250 days.
(B) Survival bar charts comparing control and treatment in Taiwanese SMA mice. **, still alive at N230 days. References for the studies are denoted in the brackets. Abbreviations: AAV,
adeno-associated virus; scAAV, self-complementary adeno-associated virus; coSMN, codon-optimized SMN; scAAV9-SMNopti, an optimized SMN-encoding scAAV9; IM, intramuscular
injection; ICV, intracerebroventricular injection; IV, intravenous injection; IP, intraperitoneal injection; SC, subcutaneous injection; OE, overexpression; PO, per os; TP, transplantation;
ASO, antisense oligonucleotide; MOE, an ASO with phophorothioate backbone and 2′-O-methoxyethyl modiﬁcation; MO, morpholino; 2′-OMe, an ASO with phophorothioate backbone
and 2′-O-methyl modiﬁcation; ISS-N1, intronic splicing silencer N1; PMO, phosphorodiamidatemorpholino oligonucleotides; Tra2β1, transformer-2 protein homolog β; SF2/ASF, splicing
factor2/alternative splicing factor.
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of Taiwanese type I SMA mice with JNJ-26481585, a novel second-
generation HDAC inhibitor, did not provide any lifespan beneﬁt [98].Thus far, only modest beneﬁts have been observed in SMA patients
treatedwith HDAC inhibitors. HDAC inhibitors continue to be evaluated
as potential SMA therapeutics.
Table 2
Pathways affected by compounds used for potential SMA therapy.
Treatment Process Models used References
Histone deacetylase inhibitors
Trichostatin A Transcription Δ7 SMA mice [68,69]
Suberoylanilide hydroxamic acid Transcription Taiwanese mice [80]
Sodium butyrate Transcription Taiwanese mice [81]
Valproic acid Transcription Taiwanese mice [90]
Translation read-through compounds
G418 (geneticin) Translation Δ7 SMA mice [65]
TC007 Translation Δ7 SMA mice [66,67]
Quinazolines
RG3039 Transcription Δ7 SMA mice
Taiwanese mice
2B
[63]
[79]
[79]
D156844 Transcription Δ7 SMA mice [64]
Other small molecules that increase SMN2 expression
LDN-76070 Transcription Δ7 SMA mice [54]
Indoprofen Splicing and/or
translation
Line 89 [109]
Antibiotics
Ceftriaxone Cell signaling Δ7 SMA mice [60]
PTK-SMA1 (tetracycline-like) Splicing Taiwanese mice [110]
Signal transducing molecules
Sodium vanadate Splicing Taiwanese mice [117]
Neuroprotective compounds
BIP-135 Cell signaling Δ7 SMA mice [58]
N-Methyl-D-aspartic acid Cell signaling Δ7 SMA mice [59]
Riluzole Cell signaling F7 or exon 7
ﬂoxed
[121]
Polypeptides and proteins
Insulin-like growth factor 1 Cell signaling Δ7 SMA mice [57]
Follistatin Cell signaling Δ7 SMA mice [61]
Prolactin Transcription Δ7 SMA mice [62]
Gene therapy and trans-splicing
SMN1 gene therapy SMN-associated
functions
Δ7 SMA mice
Taiwanese mice
[70–75]
[82]
Trans-splicing Splicing Δ7 SMA mice [133]
Stem cell based therapy of SMA
Stem cell transplantation SMN-associated
functions
Δ7 SMA mice [55,56]
SMN-independent treatment strategies
Forced running Multiple Δ7 SMA mice
Taiwanese mice
[148]
[78]
ASO-based therapy
Antisense oligonucleotides Splicing Δ7 SMA mice
Taiwanese mice
[50–53]
[76,77]
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Skipping of SMN2 exon 7 produces a truncated protein (SMNΔ7)with
a novel extension of four amino acids (EMLA) coded by exon 8. EMLA
serves as a degradation signal within SMNΔ7 [10]. Several aminoglyco-
sides are known to interact with ribosomes and allow read-through
at stop codons [99]. Read-through of the ﬁrst stop codon in the exon
7-deleted transcript of SMN2 is predicted to add another ﬁve amino
acids to the C-terminus of SMNΔ7. Incidentally, SMA patient cells
treated with aminoglycosides showed increased SMN bodies (gems),
suggesting that addition of extra amino acids due to read-through has
a stabilizing effect on SMNΔ7 [100,101]. A follow up study conﬁrmed
stabilization of SMNΔ7 upon addition of the ﬁve extra amino acids at
the C-terminus of SMNΔ7 [102]. TC007, a novel aminoglycoside (an an-
alog of neomycin not expected to cross theBBB),modestly extended the
mean lifespan of Δ7 SMA mice when administered through intra-
cerebroventricular (ICV) route (Fig. 1) [67]. However, chronic subcuta-
neous (SC) administration of this compound did not produce any lifeexpectancy beneﬁt (Fig. 1) [66]. Geneticin (G418), another aminoglyco-
side, improved motor function but did not provide survival beneﬁt in
Δ7 SMA mice (Fig. 1) [65]. Furthermore, chronic administration of
G418 turned out to be toxic even for thewild typemice [65]. These ﬁnd-
ings underscore the limitations of the current generation of aminogly-
cosides as a potential drug candidate for SMA therapy.
2.3. Quinazolines
Quinazolines are a family of compounds that inhibit RNA decapping
enzyme DcpS (involved in RNA turnover), and this inhibition can conse-
quently increase SMN2 expression [103]. A high-throughput screening
identiﬁed a few quinazolines as lead compounds that increased full-
length SMN2 transcript and SMN [104]. These compounds had poor BBB
penetration and required high doses to achieve sufﬁcient upregulation
of SMN. Based on a lead quinazoline, derivatives were developed
to overcome the obstacles associated with the low BBB penetration
[105]. One of these derivatives, D156844, crossed the BBB without any
adverse effect in Δ7 SMA neonates. However, D156844 produced only
a modest lifespan extension in Δ7 SMA mice (Fig. 1) [64]. Further
optimization of this compound led to the identiﬁcation of D157495,
also called RG3039. In one study, daily intraperitoneal (IP) adminis-
tration of RG3039 modestly extended the lifespan of Δ7 SMA mice
and improved themorphology and function of the neuromuscular junc-
tion (NMJ) [63]. In another study, daily oral administration of RG3039
modestly extended the lifespan of Taiwanese type I mice (Fig. 1) [79].
Additionally, RG3039 markedly increased the lifespan in less severe
Smn2B/− mouse model (median lifespan increased from 18 to
112 days) [79]. Currently, RG3039 is undergoing phase I clinical trial
in which safety and efﬁcacy of various doses will be evaluated.
2.4. Hydroxyurea
Hydroxyurea has been shown to increase SMN2 expression in SMA
patient ﬁbroblasts, purportedly via an increase in nitric oxide [106].
Due to the positive in vitro effects and the BBB permeability of hydroxy-
urea, this compound was tested in SMA patients in several clinical
trials (Clinicaltrials.gov ID numbers NCT00485511, NCT00568698, and
NCT00568802). While one small study registered encouraging results
in SMA patients treated with hydroxyurea [107], a larger, placebo-
controlled study did not reveal any signiﬁcant effects in SMA treated
patients [108]. Theseﬁndings limit the scope of hydroxyurea as an effec-
tive drug for SMA therapy.
2.5. Compounds from cell-based drug screenings
A luciferase reporter system coupled to SMN2 minigene carrying
CMV promoter was employed in a high-throughput screening
to identify indoprofen, a non-steroidal anti-inﬂammatory drug
(NSAID) that promoted SMN2 exon 7 inclusion in C33a cervical carcino-
ma cells [109]. Other NSAID compounds failed to stimulate SMN2 exon
7 inclusion, suggesting that the effect of indoprofen is mediated through
a cyclooxygenase-independent pathway. Subsequent evaluation of
indoprofen in SMA patient cells failed to show any stimulatory effect on
SMN2 exon 7 splicing from endogenous SMN2. Interestingly, through an
unknown mechanism indoprofen produced a noticeable upregulation
of SMN (protein) in SMApatient cells [109]. In vivo efﬁcacy of indoprofen
was tested employing a highly severe SMAmodel in which all SMA pups
die by embryonic day 11 (E11). A single IP administration of indoprofen
(5 mg/kg) was able to increase the mean litter size of embryos at E14
[109]. However, efﬁcacy of indoprofen in less severe mouse models re-
mains to be evaluated. Another reporter assay that used SMN2minigene
coupled with SMN2 promoter identiﬁed a set of compounds including
LDN-75654 and LDN-76070. These compounds were found to increase
SMN levels in SMA patient cells [54]. IP administration of LDN-76070 in
Δ7 SMA mice modestly extended lifespan compared to untreated mice
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be evaluated due to their extremely poor water solubility.
2.6. Antibiotics
Several antibiotics have been evaluated as potential therapeutic
compounds for the treatment of SMA [60,110]. Screening of
tetracycline-like compounds using a cell-free splicing assay identiﬁed
PTK-SMA1 [110]. PTK-SMA1 increased SMN levels in SMA patient cells
as well as in a type III SMA mouse model [110]. However, therapeutic
efﬁcacy of tetracycline-like compounds on phenotype and life expec-
tancy of a mouse model of SMA is yet to be evaluated. Ceftriaxone is a
third-generation cephalosporin antibiotic that has been tested for its
therapeutic efﬁcacy in a mouse model of amyotrophic lateral sclerosis
(ALS), a devastating neurodegenerative disease [111]. Ceftriaxone
prevented motor neuron loss and increased survival of ALS mice possi-
bly through increased glutamate clearance and reduced excitotoxicity
[111]. Treatment of Δ7 SMA mice with high doses of ceftriaxone
(200 mg/kg) showed some beneﬁts on muscle and NMJ morphology,
however, the survival beneﬁt was very modest (Fig. 1) [60].
2.7. Signal transducing molecules
Splicing factor Tra2β1 stimulates SMN2 exon 7 inclusion by directly
binding to exon 7 [112]. Dephosphorylation of Tra2β1 by protein
phosphatase 1 (PP1) was implicated in the promotion of SMN2 exon 7
skipping [113]. Recently, cantharidin analogs thatmodulate PP1 activity
were shown to increase SMN2 exon 7 inclusion and SMN levels in SMA
patient cells [114]. Like several phosphatase inhibitors, cantharidins are
known to affect transcription [115]. However, it remains to be seen if
cantharidin analogs that promote SMN2 exon 7 inclusion also stimulate
SMN2 transcription. Sodium vanadate is a tyrosine phosphatase inhibi-
tor that markedly increases SMN2 exon 7 inclusion in a cell-based
splicing assay [116]. However, sodium vanadate was considered inap-
propriate for SMA therapy due to high toxicity. To overcome this toxic-
ity, Taiwanese type III SMA mice were simultaneously treated with
sodium vanadate and the detoxiﬁcation agent L-ascorbic acid [117]. In-
deed, the combination therapy prevented the morbidity and mortality
induced by sodium vanadate. Also, the combination therapy delayed
the onset of tail necrosis, increased lumbar spinal cord motor neurons
and improved muscle histology. However, effects in a more severe
mouse model of SMA remain to be determined.
2.8. Neuroprotective compounds
The neuroprotection conferred by smallmolecules can occur via sev-
eral mechanisms and could potentially spare or protect motor neurons
and thus ameliorate the disease. Glycogen synthase kinase-3 (GSK-3)
has been linked to human pathologies, and inhibition of this signaling
molecule is purported to activate cyclic AMP response element binding
protein (CREB) and increase transcription of neurotrophic factors. In-
deed, GSK-3 inhibition extended the lifespan of a mouse model of ALS
[118]. When BIP-135 (a GSK-3 inhibitor) was administered to Δ7 SMA
mice, median lifespan increased modestly compared to untreated
mice (Fig. 1) [58]. Further studies would be needed to appropriately
evaluate the effect of various treatment regimes. As a potential treat-
ment for SMA, activation of the N-methyl-D-aspartic acid (NMDA) re-
ceptor has also been examined. Intrathecal NMDA administration
in two SMAmouse models accelerated maturation of motor units, con-
ferred neuroprotection tomotor neurons and signiﬁcantly extended the
lifespan (Fig. 1) [59]. NMDA also led to CREB activation with a resultant
increase in SMN levels [59]. However, the clinical utility of intrathecal
NMDA administration is yet to be evaluated in SMA patients.
Olesoxime is a mitochondrial pore modulator that provides protec-
tive effects in motor neurons [119]. While the neuroprotective effect
of olesoxime has not been tested in SMA mouse models, it is currentlyundergoing a phase 2 clinical trial for the treatment of SMA
(Clinicaltrials.gov ID number NCT01302600). SMA type II and III patients
are enrolled in this ongoing study; each patientwill undergo two years of
treatment to examine the beneﬁcial effects of this compound.
Riluzole is the only FDA-approved compound for ALS treatment.
Although the mechanism of riluzole action remains vague, it appears
to exert its neuroprotective effect by modulating glutamate transmis-
sion [120]. Therapeutic efﬁcacy of riluzole was evaluated in a SMA
mouse model that was generated by neuron-speciﬁc knockout of Smn
exon 7 [121]. Riluzole improved the architecture of motor neuron syn-
aptic terminals and modestly increased the lifespan of SMA mice
[121]. A phase I clinical trial inwhich infantswith SMA type Iwere treat-
ed with riluzole produced intriguing results. Three of the seven patients
lived well past the usual age of death with limited need for respiratory
support, although conclusions were not deﬁnitive due to very small
sample size [122]. A phase 2/3 clinical trial of riluzole with type II and
type III patients has been conducted and ﬁndings of this study are still
awaited (Clinicaltrials.gov ID number NCT00774423).
3. Polypeptide and protein-based therapies
Transcription of SMN2 is modulated by transcription factor STAT5, a
phosphorylation substrate of Janus kinase (JAK) [123]. Prolactin, a poly-
peptide hormone that activates JAK2/STAT5 signaling pathwayhas been
shown to improvemotor function andmodestly increase the lifespan of
Δ7 SMA mice (Fig. 1) [62]. Prolactin also increased SMN levels in the
brain possibly through activation of transcription of SMN2 [62]. Howev-
er, it remains to be seen if other members of the JAK/STAT signaling
pathway would have a better therapeutic efﬁcacy.
Myostatin, a member of the transforming growth factor beta (TGFβ)
family, is expressed almost exclusively inmuscle and functions as a neg-
ative regulator of skeletal muscle growth [124]. Follistatin, a known
myostatin inhibitor, improved motor function and modestly increased
the lifespan of Δ7 SMA mice (Fig. 1) [61]. In another study, Δ7 SMA
mice treatedwith activin IIB (ActIIB-Fc), a soluble receptor ofmyostatin,
increased the mass of several muscles, but did not rescue motor func-
tion or extend survival [125]. Furthermore, knocking out of myostatin
gene in Δ7 SMA model did not reduce the severity of disease [126].
These ﬁndings rule out the TGFβ signaling pathway modulating com-
pounds as the potential therapeutic candidates of SMA.
Insulin-like growth factor 1 (IGF-1), a protein hormone, serves as
an important regulator of skeletal muscle development and function
[127]. Incidentally, IGF-1 serum levels are signiﬁcantly reduced in both
Taiwanese type I SMA [77] and Δ7 SMA mice [128]. To investigate the
role of IGF-1 in SMA pathology, a novel mousemodel that overexpressed
a ratmuscle-speciﬁc isoformof IGF-1 in skeletalmuscle ofΔ7 SMAmodel
was developed [57]. IGF-1 overexpressionmodestly affected the pheno-
type: median lifespan was extended ~1.4-fold and several muscles
increased in weight (Fig. 1) [57]. In a separate study, treatment of Δ7
SMA mice with IPLEX (recombinant human IGF-1 complexed with
recombinant IGF binding protein 3) prevented muscle wasting and
neuromuscular junction abnormalities [128]. However, this approach
did not improve motor function and lifespan of Δ7 SMA mice [128].
4. Gene therapy and trans-splicing
Gene therapy promises a permanent solution for SMA through viral
delivery and insertion of the entire SMN1 gene or cDNA sequence into
the genome of SMA patients. This process is generally irreversible and
there are apparent risks if the exogenously delivered gene is inserted
at a wrong location and/or overexpressed. The ﬁrst gene therapy,
conducted in Δ7 SMA mice, introduced the entire human SMN1 gene
and conferred some protection to brainstem motor neurons and in-
creased lifespan from 13 to 18 days (Fig. 1) [75]. Despite the modest
outcomes, ﬁndings provided the ﬁrst direct evidence that the postnatal
increase in SMN levels confers deﬁnite therapeutic beneﬁts. In another
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creased the lifespan ofΔ7 SMAmice (Fig. 1) [74]. This ﬁnding suggested
that increasing SMN levels in the brain is critical for prolonging the life
of SMApatients. However, numerous studies that delivered SMN1 intra-
venously (IV) also demonstrated impressive results [71,72,129]. In
particular, a codon optimized SMN1 sequence injected into the temporal
vein increased median survival ~15-fold (Fig. 1) [71]. Intramuscular
delivery of the same sequence produced comparable results (Fig. 1)
[70]. Another study conducted in Δ7 SMA mice demonstrated similar
beneﬁts from IV and ICV administrations of scAAV9-SMN [130]. On
the other hand, experiments conducted in Taiwanese type I SMA mice
yielded variable results and less promising survival beneﬁts with ICV
administration of SMN1 sequence (Fig. 1) [82]. These ﬁndings under-
score the caution that must be exercised when extrapolating the results
of pre-clinical studies conducted in a speciﬁc mouse model to design
clinical trials in humans. Overall, the results of gene therapy appear
promising and may offer one of the best therapeutic alternatives to a
speciﬁc group of SMA patients who are too weak to receive frequent in-
vasive treatments.
Trans-splicing is a gene-therapy-like approach with the potential
to treat SMA patients. This approach involves exogenous delivery of a
partial gene or mRNA that triggers production of a chimeric transcript
that is equivalent to the full-length mRNA generated from the endoge-
nous gene [131,132]. Considering that the trans-splicing process uses
endogenous pre-mRNA as a substrate, it caps the level of mRNAs and
protein produced. Therefore, trans-splicing has inbuilt potential to
fully avoid complications of protein overexpression, which is an antici-
pated risk associated with the gene therapy. Of note, it must be brought
forth that there is no evidence to suggest that gene therapy-based
approaches would cause SMN overexpression that results into a recog-
nizable harmful effect in pre-clinical studies. Experiments conducted in
SMAmousemodels have shown encouraging results of a trans-splicing-
based approach [133]. However, the improvements in lifespanwere less
impressive [133]. In general, trans-splicing is a very inefﬁcient processFig. 2.ASO-mediated SMN2 splicing correction as a therapy for SMA. (A) Diagrammatic represen
of intron 7. The negative cis-element ISS-N1 (yellow box) contains two hnRNP A1 binding sites
Green ovals represent binding sites for TIA1, an enhancer of exon 7 splicing. (B) Representative I
ASO sequences are in upper caps. The chemistry for each ASO is listed to the left of the sequ
the sequence; references are denoted in brackets. Abbreviations: ASO, antisense oligonucleotide
T-cell restricted intracellular antigen 1; LDI, long-distance interaction; 2′-OMe, an ASO with phos
backbone and 2′-O-methoxyethyl modiﬁcation; MO, morpholino; GM, SMA patient ﬁbroblast cethat remains an option only when other therapies fail to meet the
high expectations.
5. Stem cell based therapy
Stem cell therapy is based on the assumption that intrathecal trans-
plantation of healthy donor stem cells in the spinal cord of SMApatients
would compensate for the eventual death of the endogenous motor
neurons. Two major studies evaluated the effect of stem cells in
mouse models of SMA [55,56]. In one study, spinal cord neural stem
cells injected into cerebrospinal ﬂuid increased the mean survival of
Δ7 SMA mice ~39% (Fig. 1) [56]. In a separate study, intrathecal trans-
plantation of embryonic stem cell-derived neural stem cells augmented
the number and size of motor neurons, improved muscle innervation
and increased mean survival of Δ7 SMA mice by 64% (Fig. 1) [55].
These modest beneﬁts in pre-clinical studies somewhat undermine
the promise of stem cell therapy for the treatment of SMA.
6. ASO-based therapy
ASO-based strategies employ speciﬁc SMN2 sequences as targets
for SMA therapy [49]. Earlier studies focused on bifunctional ASOs that
blocked the C6U mutation site within SMN2 exon 7 and provided a
tailed sequence for the recruitment of the positive splicing factors at
the weak 3′ splice site (3′ ss) of exon 7 [134,135]. These studies were
driven by a well-founded belief that a weak 3′ ss was the sole cause of
SMN2 exon 7 skipping and forced recruitment of a positive regulator
at the 3′ ss was the best mechanistic solution for the restoration of
SMN2 exon 7 inclusion. Subsequent studies shifted attention towards
the 5′ ss as it became obvious that a series of inhibitory elements are po-
sitioned in the vicinity of the 5′ ss [136–139]. A major breakthrough
came with the discovery of intronic splicing silencer N1 (ISS-N1), a
ﬁfteen-nucleotide sequence spanning from the 10th to the 24th posi-
tions of SMN2 intron 7 (Fig. 2) [137]. Since an ASO annealing to antation of splicing cis-elements in SMN2 intron 7. Numbering begins from the ﬁrst position
(magenta boxes) and has emerged as a leading ASO target for splicing correction in SMA.
SS-N1-targeting ASOs tested in SMAmousemodels. Intron 7 sequence is in lower caps and
ence. The outcomes for studies in which the ASOs were tested are listed to the right of
; ISS-N1, intronic splicing silencer N1; hnRNP A1, heterogenous ribonucleoprotein A1; TIA1,
phorothioate backbone and 2′-O-methyl modiﬁcation; MOE, an ASO with phosphorothioate
lls (cell line GM03813); TW, Taiwanese SMA mouse model; Δ7, Δ7 SMA mouse model.
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al machinery, ISS-N1 serves as an ideal target for an ASO-mediated
splicing correction in SMA. Indeed, sequestration of ISS-N1 by an ASO
fully restored SMN2 exon 7 inclusion and substantially increased levels
of SMN in SMA patient cells [137].
A vast number of independent reports have put ISS-N1 as one of the
best-studied antisense targets for splicing correction in a human disease
[49]. Therefore, lessons learned from these reports have wide implica-
tions for SMA therapy as well as for therapy of many other genetic
diseases. Our understanding of the mechanism by which an ISS-N1-
targeting ASO promotes SMN2 exon 7 inclusion continues to evolve.
ISS-N1 harbors two hnRNP A1/A2 binding sites that do not include a
cytosine residue (10C) at the 10th intronic position (the ﬁrst nucleotide
of ISS-N1) (Fig. 2). It was initially hypothesized that an ASO-mediated se-
questration of hnRNP A1 motifs of ISS-N1 is necessary and sufﬁcient to
confer full stimulatory effect on SMN2 exon 7 splicing [139]. However, a
subsequent study suggested that the sequestration of 10C is also critical
for the robust stimulatory effect on SMN2 exon 7 splicing [140]. Inciden-
tally, 10C falls within an 8-nucleotide GC-rich sequence that partially
overlaps with the ﬁrst hnRNP A1motif of ISS-N1 (Fig. 2A) [141]. Seques-
tration of this GC-rich sequence alone by an ASO fully restored SMN2
exon 7 inclusion [141,142]. A recent study puts 10C and GC-rich sequence
in a structural context that involves a unique long-distance interaction
[143]. This study also brings a new perspective by demonstrating an
ASO-mediated remodeling of RNA structure in the vicinity of the 5′ ss
[143]. Intronic sequences downstream of ISS-N1 contain binding sites
for T-cell restricted intracellular antigen 1 (TIA1), which is a positive reg-
ulator of SMN2 exon 7 splicing [144]. A single amino acid substitution
within TIA1 has been shown to negatively affect SMN2 exon 7 splicing
in patients of Welander distal myopathy [145]. Therefore, TIA1 emerges
as the ﬁrst and the only splicing factor whose mutation could be directly
linked to SMN2 exon 7 splicing in the context of a human disease. Based
on a recent study, an ASO targeting ISS-N1 or GC-rich sequence brings
a structural change that promotes TIA1 recruitment and consequently
favors inclusion of SMN2 exon 7 [143].
In order to validate the therapeutic efﬁcacy of ISS-N1-targeting
ASOs in vivo, oligonucleotides with three different modiﬁcations
have been tested (Fig. 2) [49]. These modiﬁcations are: 2′-O-methyl
with phosphorothioate backbone (2′-OMe), 2′-O-methoxyethyl
with phosphorothioate backbone (MOE) and morpholino. A system-
atic study reported by Krainer and colleagues employed an ISS-N1-
targeting 18-mer MOE ASO and demonstrated ~25-fold increase in
the life expectancy of the severe Taiwanese model of SMA (Fig. 1) [77].
Surprisingly, subcutaneous injections produced the most beneﬁcial ef-
fects, whereas ICV delivery resulted in only a moderate response. These
ﬁndings supported the peripheral requirement of SMN for the avoidance
of SMA. However, results of other studies conducted recently with ISS-
N1-targeting morpholino ASOs were somewhat different. In particular,
the Burghes group used a 20-mer morpholino ASO and showed
~8-fold increase in the life expectancy of Δ7 SMA mouse upon ICV ad-
ministration (Fig. 1) [52]. The Muntoni group observed similar lifespan
beneﬁts in Taiwanese model mice upon ICV administration of a 25-mer
morpholino ASO (PMO25) (Fig. 1) [76]. These ﬁndings are consistent
with the early requirement of SMN in motor neurons. Interestingly, a
single facial injection of PMO25 was found to be highly efﬁcacious as
it led to ~22-fold increase in the life expectancy of Taiwanese mouse
model (Fig. 1) [76]. While these results support the peripheral require-
ment of SMN, they are confounded by the fact that BBB inmice remains
permeable for a few days after birth. Therefore, it is likely that the ben-
eﬁcial effect at high doses of peripheral administration is due to leakage
of ASOs into the brain. Overall, the results of these studies showed an
unprecedented therapeutic beneﬁt of ASOs targeting ISS-N1.
The observation that the efﬁcacy of an ISS-N1-targeting ASO is on par
with the gene replacement therapy underscores that ASO-mediated
splicing correction is among the most promising options of SMA therapy
(Fig. 1). Moving forward with clinical trials, concerns related to ASOdelivery and toxicity would have to be addressed. ISIS Pharmaceuticals
has recently concluded phase 1 and initiated a phase 2 clinical trial
of ISIS-SMNRx, an ISS-N1 targeting MOE ASO (Clinicaltrials.gov ID
NCT01839656). Encouraging outcomes of ISIS-SMNRx in a phase 1 clini-
cal trial demand an expansion of ASO-based strategies to include addi-
tional targets and different oligonucleotide chemistries. Of note, a slight
change in ASO sequence could confer entirely different pharmacokinetic
and pharmacodynamic properties. Also, a change in the ASO backbone
would generate an entirely newclass of compound. Given the variable se-
verity and age diversity among SMA patients, a variety of chemotherapy
options would be needed for the treatment of SMA. In principle, multiple
ASO-based drugs with different pharmacokinetic and pharmacodynamic
properties could be developed against a single target, provided issues re-
lated to the proprietary rights on antisense target, oligonucleotide chem-
istry and delivery protocols are appropriately reconciled. Two recent
clinical trials of a morpholino ASO have shown promising results for
the treatment of Duchenne Muscular Dystrophy [146,147]. Incidentally,
ISS-N1 targeting morpholino ASOs have demonstrated substantially
better ICV efﬁcacy than MOE ASOs (Fig. 1). Therefore, employment of
morpholino chemistry for the development of the next ASO-based drug
for SMA treatment remains an attractive proposition.
7. Other therapies
There are very-limited studies that utilize treatments that do not os-
tensibly affect SMN. Of these studies, the effects of physical exercise on
the survival and phenotype of SMA mouse models have been most
widely examined. Taiwanese type II SMA mice trained to run on an ex-
ercisewheel showed increased full-length SMN2 transcript in the spinal
cord, decreased neuronal loss and an extended lifespan (Fig. 1) [78]. In
another study, forced running enhanced the development of several
muscles compared to sedentary Δ7 SMA mice [148]. Interestingly, ad-
ministration of MK-801, a NMDA receptor antagonist, abolished the
lifespan extension conferred by exercise [148]. These results suggest
the involvement of glutamate neurotransmission as an importantmedi-
ator of exercise beneﬁts. A recent study in Δ7 SMA mice showed tangi-
ble beneﬁts of exercise on cardiac function such as improved
conduction velocity, reduced ﬁbrosis, improved bradycardia and de-
creased arrhythmias [149]. These ﬁndings support that exercise could
be very useful as an adjunct therapy of SMA [150].
Proper supportive therapy is crucial to increase the survival and
quality of life of SMA patients. Infants diagnosed with type I SMA will
eventually require some sort of ventilation support to facilitate their
breathing. Studies in type I SMA patients have shown respiratory inter-
ventions (invasive or noninvasive) increase survival compared to those
patients who do not receive respiratory support [151,152]. Of course,
patients with the more severe manifestations of the disease will likely
require more invasive interventions. Respiratory support, as well as
other supportive therapy such as nutritional supplementation or total
parenteral nutrition, can certainly improve the quality of life for SMA
patients.
8. Conclusions
SMA is a progressive neurodegenerative disease of infants and chil-
dren. Although SMA has no known cure, the patient population pos-
sesses SMN2, which can be potentially targeted for therapy. The last
ten years have witnessed a dramatic progress in the development of
therapeutic strategies for SMA. Much of the success in the ﬁeld of SMA
therapy could be attributed to a better understanding of SMN function,
SMN2 exon 7 splicing regulation, SMA pathogenesis and the develop-
ments in the related ﬁelds. Small compounds continue to attract atten-
tion due to expected ease of their delivery across the BBB. However, all
of small compounds tested thus far showed a very small lifespan exten-
sion beneﬁt. SMN is an essential protein, which is involved in regulation
of a number of vital processes within a cell. The low efﬁcacy of small
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streamevents regulated by SMN. It is also likely that some of these com-
pounds have antagonistic effects on various critical pathways regulated
by SMN. Therefore, there is a need for additional drug screening assays,
which identify new classes of small compounds that affect upstream
events such as transcription and splicing of SMN2. Exceptional pre-
clinical results of ISS-N1-targeting ASOs and promising outcome of
phase 1 clinical trial of ISIS-SMNRx provide one of the best hopes for
SMA therapy. Recent discovery of ISS-N2, a novel antisense target
[143], further expands the potential for the development of additional
antisense-based drugs. Currently, invasive intrathecal administration
remains the most effective mode of delivery of ASOs to SMA patients.
Therefore, there is a need to work on modiﬁcations and non-invasive
delivery protocols that allow an easy transport of ASOs across the BBB.
A success in this direction would dramatically elevate the status of
ASO-based therapy of SMAand possibly several other diseases requiring
transport of a small nucleic acid molecule across BBB.
Despite admirable attempts by a number of investigators [153–155],
one of themajor challenges for the therapeutic development in SMAhas
been the availability of the robust biomarkers. The ﬁrst therapy with
substantial lifespan enhancements in SMA would likely offer additional
biomarkers. Knowledge of such biomarkers would be extremely helpful
for future drug screenings. Therapeutic progress in SMA thus far sup-
ports that compounds speciﬁcally aimed at correction of SMN2 exon 7
splicing offer the most promising outcome. The challenge remains
how to identify/design a small compound that fully corrects SMN2
exon 7 splicing aswell as is able to cross BBB. The answer could lie with-
in intronic sequences that fold into secondary and high-order RNA
structures. Indeed, small compounds can affect splicing through speciﬁc
interactions with a unique RNA structure [156]. The complex process of
pre-mRNA splicing of a speciﬁc exon comes at the expense of hundreds
of structural rearrangements. As we move forward with uncovering of
structural rearrangements during pre-mRNA splicing of SMN2 exon 7,
we hope to see new avenues open up for discovery of unique compounds
for SMA therapy. Thanks to the partnership between academia and in-
dustry, SMA has an impressive track record of clinical trials of a variety
of compounds covering different pathways. Many of these compounds
are being tested for the ﬁrst time to cure a genetic disease. Therefore, a
potential success will likely translate into therapeutic development for a
number of genetic diseases requiring splicing modulation.Acknowledgements
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